Superior Oncology Xenograft Models: Why OncoRat is a Better Trap for Cancer
Poor engraftment efficiencies in SCID mice and athymic rats have plagued anticancer studies since the technology’s introduction. Inefficient oncology xenograft models lead to increased research costs,extended timelines, and lower the probability of study success. The SRG OncoRat model system sets an entirely new standard for translational research, delivering ~80-100% engraftment in a more favorable rat model where tumors grow faster, more efficiently, and larger than those of mouse models. Download the White Paper summarizing the recent Clinical Cancer Research paper featuring the OncoRat!
SRG OncoRat Technology: More Reliable, More Robust, More Efficient
SRG OncoRat , developed using Hera Biolabs’ technology, is a SCID rat on the Sprague-Dawley background that harbors a double knockout for the Rag2 and Il2rgamma genes. Similar to NSG mice, OncoRat demonstrates enhanced immunodeficiency, lacking B-cells, T-cells, and NK-cells. Combining these genetic changes in this immunodeficient rat allows the use of fewer animals through enhanced engraftment rates and improved tumor growth profiles for both cell-line tumor models and patient-derived xenografts (PDXs) (Figure 1). Given the many advantages of using SCID rats, OncoRat is an ideal model for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.